linjc16/ctgov huggingface dataset:
1,5-AG as a Marker of Postprandial Hyperglycemia and Glucose Variability in Well-controlled Type 2 Diabetes Mellitus

Study Overview
=================
Brief Summary
-----------------
The aim of this study was to evaluate the correlation between 1,5-Anhydroglucitol in patients with HbA1C <7%, and glycemic excursions as assessed by the continuous glucose monitoring system compared to fructosamine.

Detailed Description
-----------------
1,5-Anhydroglucitol (AG) is a glucose analogue present in the plasma of healthy subjects. Physiologically, the plasma levels of 1,5-AG are very stable and only a small quantity is excreted in the urine. It is competitively reabsorbed with glucose in the renal tubules. Therefore, in the hyperglycemic state where glycosuria is present, glucose competitively inhibits renal tubular reabsorption of 1,5-AG and consequently the plasma 1,5-AG levels decrease. When glycemia is normalized and glycosuria is resolved, 1,5-AG levels increase. The usefulness of 1, 5-AG in reflecting glycemic excursions have been demonstrated in moderately controlled patients to some extent, although some studies reveal controversial results. Therefore, the aim of this study was to evaluate the association of 1,5-AG and postprandial hyperglycemia determined using the Continuous Glucose Monitoring System (CGMS) in DM patients with HbA1C<7% and evaluate the usefulness of 1,5-AG as a marker of glycemic control compared to HbA1C and fructosamine.

Official Title
-----------------
Correlation Between 1,5-anhydroglucitol and Postprandial Hyperglycemia by Continuous Glucose Monitoring System and Clinical Usefulness of 1,5-anhydroglucitol in Well-controlled Diabetic Patients

Conditions
-----------------
Type 2 Diabetes Mellitus

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: HbA1C < 7% HbA1c modification <0.5% in the previous 3 months no recent addition of oral hypoglycemic medications or change in insulin dose >10% previous 3 months Exclusion Criteria: pregnancy anemia (Hb <10.0 g/dL) liver disease (ALT >2 UNL) hypoalbuminemia (albumin <3.5 g/dL) serum creatinine >2 mg/dL acute or chronic renal tubulointerstitial disease severe medical illness

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| postprandial hyperglycemia |  | 3days | 
| glucose variability |  | 3 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
1,5-Anhydroglucitol
Frequency of Parasite Infection in Hyraxes and Sandflies During Outbreak of Leishmania Tropica Epidemic in The West Bank

Study Overview
=================
Brief Summary
-----------------
The objective of the project is to study the pathogenesis of Leishmania tropica infection in a focus of infection, to learn about relationship of infection in humans with ecological factors such as infection in hyraxes reservoir hosts and vector sandflies

Conditions
-----------------
Cutaneous Leishmaniasis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: People living on regular basis in Peduel (the site of current leishmania tropica epidemic)with and without cutaneous signs of leishmania infection Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 3 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Leishmania tropica, Hyrax, Sandfly
Preemptive Analgesia of Gabapentoids in Orthopedic Surgery

Study Overview
=================
Brief Summary
-----------------
To address the preemptive analgesic effect of preoperative gabapentoids versus no gabapentoids in orthopedic surgery

Detailed Description
-----------------
Computer search for all studies used preoperative gabapentoids versus no gabapentoids in orthopedic surgery during the last 10 years (from 2011 - 2020)

Official Title
-----------------
Preemptive Analgesia of Gabapentoids After Major Orthopedic Surgery: Systematic Review and Meta Analysis

Conditions
-----------------
Acute Postoperative Pain

Intervention / Treatment
-----------------
* Other: gabapentoids


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: RCT, during last 10 years, involving orthopedic surgery Exclusion Criteria: non randomized trials, unavailable study data

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| preemptive group<br>patients in this group will receive preoperative gabapentoids | Other: gabapentoids<br>* Preemptive analgesia<br>|
| control group<br>patients in this group will not receive gabapentoids | Other: gabapentoids<br>* Preemptive analgesia<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Postoperative pain score on rest | Pain score by VAS on rest | every hour for the first 24 hours | 
| Postoperative pain during movement | Pain score by VAS during movements | every hour for the first 24 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Worst pain score | Highest pain score | during the first 24 hours | 
| Least pain score | Lowest pain score | during the first 24 hours | 
| Time spend in severe pain | how many hours the patients complaint of severe pain | during the first 24 hours | 
| Patient's satisfaction | Satisfaction by the quality of analgesia | during the first 24 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
acute postoperative pain, Preemptive analgesia, Orthopedic surgery, Preoperative gabapentoids
Impact of Implantation of an LAA Occluder on ANP and BNP Level and Quality of Life

Study Overview
=================
Brief Summary
-----------------
Closure of the LAA by several devices is a alternative therapy to oral anticoagulation in patients with Atrail fibrillation. Nothing is known about the acute influence of a device closure of the LAA on the secretion of ANB nad BNP hormones. Therefore aim of our study is to measure ANB and BNP levvels before and after Implantation of an LAA closure device.

Detailed Description
-----------------
ANB and BNP levels are measured before, directly after and late after 24 h in central or periphereal venous blood from patients undergoing interventional LAA closure.

Official Title
-----------------
Impact of Implantation of an LAA Occluder on ANP and BNP Level and Quality of Life

Conditions
-----------------
Atrial Fibrillation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients undergoing LAA closure Exclusion Criteria: none

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from baseline atrial natriuretic Peptide (ANP) | comparison of ANP level pre and post intervention | 24 h post intervention | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Left atrial appendage occluder, Watchman device, Atrial fibrillation, atrial natriureitc peptide, brain natriuretic peptide
Bisphosphonate-coated Dental Implants

Study Overview
=================
Brief Summary
-----------------
Dental implants (screws for fastening false teeth) have been coated with bisphosphonates (drugs that slow down removal of bone). Patients get one such screw and one without coating, by a surgeon who does not know which is which. The screws are compared by measuring how well fixed they are by a vibration measuring technique, and x-rays. The hypothesis is that the bisphosphonates will improve fixation.

Conditions
-----------------
Edentatio (Toothlessness)

Intervention / Treatment
-----------------
* Device: Dental implant coating with a fibrinogen carrier for pamidronate and ibandronate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Need for at least 2 dental implants, which are to be inserted in bone of reasonably similar quality. Exclusion Criteria: Systemic or immunologic disease, alcoholism, uncontrolled diabetes and smoking. Local exclusion criteria were: previous tumour, trauma and surgery. Also patients with Cawood & Howell class IV - VI maxilla-bone were excluded.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: coated implant and control<br> | Device: Dental implant coating with a fibrinogen carrier for pamidronate and ibandronate<br>* Dental implant coating with a fibrinogen carrier for pamidronate and ibandronate compared with uncoated controls in the same mouth.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Increase in resonance vibration frequency (ISQ units) from insertion to abutment connection as compared to the control in the same patient. |  | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Marginal resorption on x-rays |  | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Edentatio (Toothlessness)
Comparison of the Prediction Derived by the Cardiovascular Performance Reserve Index With the Clinical Evaluation

Study Overview
=================
Brief Summary
-----------------
The study hypothesizes that an assumed cardiovascular performance reserve is physiologically detectable. High reserve at rest characterizes a healthy person while low reserve at rest characterizes low functional capacity e.g. heart failure. The lower the reserve the severer the morbidity. The reserve may be estimated through CVRI (cardiovascular reserve index) which is computed by an algorithm composed of physiological measurements taken during the patient visit. In this study the investigators evaluate CVRI capability in prediction of functional capacity in comparison with the clinical evaluation during the same visit.

Detailed Description
-----------------
The study hypothesizes that an assumed cardiovascular performance reserve is physiologically detectable and continuously monitored by a physiological control (reserve control)not yet discovered. High reserve at rest characterizes a healthy person while low reserve at rest characterizes low functional capacity e.g. heart failure. The lower the reserve the severer the morbidity. The reserve is decreased reversibly with aerobic activity and may reach an exhaustion threshold in which the assumed reserve control induces a reversible fatigue and dyspnea which dissolve once the activity decreased. The reserve may be estimated through CVRI (cardiovascular reserve index) which is computed by an algorithm composed of physiological measurements taken during the patient visit (composed of blood pressure, heart rate, respiratory rate, central venous pressure or its estimation, weight, height and gender. In this study the investigators evaluate CVRI capability in prediction of functional capacity in comparison with the clinical evaluation during the same visit (cross sectional comparison).

Official Title
-----------------
Comparison of the Prediction Derived by the Cardiovascular Performance Reserve Index (Calculated From Physiological Parameters) With the Clinical Evaluation

Conditions
-----------------
Healthy, Heart Failure

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: adult informed consent Exclusion Criteria: an emergency case

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| healthy and mild heart failure<br>diversity of patients | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| cardiovascular reserve index | CVRI | 1 day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
functional capacity, NYHA class
Evaluating an Internet-based Intervention for Insomnia in Breast Cancer Survivors

Study Overview
=================
Brief Summary
-----------------
This study examines the efficacy of an Internet-delivered intervention to reduce symptoms of insomnia in breast cancer survivors. Breast cancer patients with insomnia (N=30) will be assigned to either gain access to the 6-week treatment program immediately (experimental group) or following study participation (control group).

Official Title
-----------------
Evaluating an Internet-based Intervention for Insomnia in Breast Cancer Survivors

Conditions
-----------------
Insomnia, Breast Cancer

Intervention / Treatment
-----------------
* Behavioral: Internet Intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Female Diagnosed with breast cancer Age 18 and older Completed primary treatment at least one month prior to enrollment Diagnosis of insomnia Exclusion criteria: Experiencing a sleep disorder other than insomnia (e.g., sleep apnea) Experiencing a major depressive episode or other serious psychiatric disturbance Modification of psychotropic medications within the previous month Undergoing current psychotherapy treatment

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Internet Intervention<br> | Behavioral: Internet Intervention<br>* online treatment for insomnia<br>* Other names: Internet;|
| Experimental: Delayed Intervention<br>Receive access to the online Internet intervention after completing post-assessments. | Behavioral: Internet Intervention<br>* online treatment for insomnia<br>* Other names: Internet;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| sleep efficiency | sleep-onset latency, wake after sleep onset, and number of awakenings | 6 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| total sleep time | total hours of sleep per 24 hour period | 6 wks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
insomnia, breast cancer survivor, Internet intervention
Bipolar Study in Adults at Least 18 Years of Age

Study Overview
=================
Brief Summary
-----------------
Bipolar study of tolerability, clinical response and patient satisfaction

Official Title
-----------------
Lamictal for Use in Treatment of Bipolar Disorder In Adults. A Practical Clinical Assessment of Tolerability and Clinical Effectiveness.

Conditions
-----------------
Bipolar Disorder

Intervention / Treatment
-----------------
* Drug: lamotrigine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of bipolar I disorder. Must be on a stable regimen of psychiatric medication for at least 2 months prior to study. If female, must not be pregnant, or must be incapable of conceiving or be taking steps to prevent conception. Exclusion Criteria: Patients with a clinically significant psychiatric or physiologic comorbidity including significant substance abuse, depression or mania which is of an unstable of progressive nature that could interfere in participation of this study. Presence of untreated thyroid disease. Patient is actively suicidal or homicidal. Patient has history of severe hepatic or renal insufficiency. Patient is currently participating in another clinical trial.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Arm 1<br>Open label single arm study | Drug: lamotrigine<br>* Lamotrigine<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The primary endpoint will be the rate of rash during 12 weeks. |  | 12 Weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from baseline in Week 5 and Week 12 Clinical Global Impression-Bipolar version (CGI-BP) Severityand Improvement scores. |  | 12 Weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
bipolar disorder, lamotrigine
Is the Nerve Growth Factor (NGF) a Useful Biomarker in Neurogenic Bladder Dysfunction After Spinal Cord Injury?

Study Overview
=================
Brief Summary
-----------------
Spinal cord injury (SCI) almost always affects bladder function as well. As a result of this bladder dysfunction, individuals with SCI have to undergo regular invasive examination of their bladder function (urodynamic examination). The nerve growth factor (NGF) is released from smooth muscle cells of the bladder, and there are reports, that the concentration of NGF is elevated in the urine of patients with bladder dysfunction. The NGF concentration can also be measured in the blood. The concentration of NGF in the blood and urine of SCI individuals has not yet been investigated. These concentrations may correlate with the severity of bladder dysfunction, and may thus be used to replace or at least reduce the number of the more invasive urodynamic examinations. The hypothesis that urine and blood NGF concentrations in individuals with SCI are higher compared to individuals with healthy bladder function will be tested.

Conditions
-----------------
Spinal Cord Injury, Neurogenic Detrusor Overactivity, Neurogenic Lower Urinary Tract Dysfunction

Participation Criteria
=================
Eligibility Criteria
-----------------
Control Group Inclusion Criteria: physiologic bladder function Exclusion Criteria: no signed consent form age <18 / >80 years urinary tract infection bladder surgery radiation therapy of the pelvic area pregnancy bleeding disorder Study Group Inclusion Criteria: neurogenic detrusor overactivity presentation for urodynamic examination Exclusion Criteria: no signed consent form age <18 / >80 years urinary tract infection bladder augmentation bladder evacuation by permanent catheterization radiation therapy of the pelvic area pregnancy bleeding disorder

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| spinal cord injury<br>individuals with neurogenic lower urinary tract dysfunction | |
| control group<br>individuals with physiologic bladder function | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| urinary concentration of nerve growth factor |  | day 0 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| serum concentration of nerve growth factor |  | day 0 | 
| demographics |  | day 0 | 
| urodynamics | only participants with spinal cord injury | day 0 | 
| International Prostate Symptom Score (I-PSS) |  | day 0 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
spinal cord injury, neurogenic lower urinary tract dysfunction, nerve growth factor, neurogenic detrusor overactivity, urodynamics